Rgenta Therapeutics
Dezhi Kang is a Vice President with Lilly Asia Ventures (LAV). Prior to joining LAV, Dezhi was an Associate Director at Navigant Consulting, providing commercial strategy support to pharma and biotech companies. Dezhi holds a Ph.D. in Molecular and Medical Pharmacology from UCLA and B.S. in Biotechnology from Peking University.
This person is not in the org chart
This person is not in any offices
Rgenta Therapeutics
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.